156 patients randomized in multi-center, double-blind, placebo-controlled Phase 2b Elumina trial; topline data anticipated in Q4 2026 (ClinicalTrials.gov: NCT06524830 ) AtaiBeckley plans to advance...
AtaiBeckley to be added to the Russell 2000® Index and the broad-market Russell 3000® Index as part of 2026 reconstitution The Russell U.S. Indexes have approximately $12.2 trillion in assets benchmarked...
Three $20,000 grants open to non-profit, mission-driven organizations working across community support, education and stigma reduction, and ecosystem innovation and independent research NEW YORK,...
NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing...
Barchart Research What to Expect from ATAI Earnings ATAI Generated May 12, 2026 Current Price $4.15 EPS Estimate $$-0.11 Consensus Rating Strong Buy Average Move 7.37% AtaiBeckley's Phase Three Initiation...
Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression on track for Q2 2026 VLS-01 Phase 2 Elumina topline results anticipated in Q4 2026 Consistent, convergent improvements...
Psychedelic drugs could get a big boost thanks to a recent executive order, and these firms all have promising candidates in line.
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by...
From manufacturers to high volatility biotechs, these are the mind-bending med stocks our Senior Market Strategist is watching now.
Wall Street is currently pivoting toward high-growth biotech plays as federal support accelerates a revolution in alternative medicine.